Prostate Cancer
Conditions
Brief summary
This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression. The study is blinded, and subjects will be randomised (1:1 ratio) to either ZD6474 300 mg or placebo. The blinded design ensures robust, unbiased data collection and assessment. Placebo control is necessary to ensure a robust assessment of PSA PFS, and is acceptable in this subject population where all subjects will also received bicalutamide 150 mg o.d. Subjects will continue study treatment until they reach objective biological disease progression or unacceptable toxicity or withdrawal of consent or until end of trial (which event occurs first). The end of study is fixed 12 months after the last randomised patient's first dose of study treatment.
Interventions
300mg orally, once daily
DRUGBicalutamide
150mg orally, once daily
DRUGPlacebo
orally, once daily
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males presented with a confirmed histological diagnosis of adenocarcinoma of the prostate with evidence of metastases (including bone, lymph nodes, or other site) radiologically or histologically documented and despite a serum testosterone ≤1.73 nmol/L (50 ng/dL) proving castration, evidence of biochemical progression of prostate cancer, documented by a rise in PSA .
Exclusion criteria
* Radiotherapy or surgery or antiandrogens (except LHRH analogue) or bilateral orchiectomy within the 30 days preceding Visit 1. Incompletely healed surgical incision. * Concomitant anticancer therapy other than surgical castration or continuous medical castration. * Biology restriction. * Clinical significant cardiovascular event or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia. * History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3), symptomatic despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled on medication are permitted. * Hypertension not controlled by medical therapy * ECG /QTc prolongation * Presence of left bundle branch block (LBBB).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months | 4 months | To assess the effect of vandetanib on biological progression free rate based on PSA level (assessable set). PSA progression free rate defined as the number of participants with : * After decline from baseline: a 25% increase above the nadir * No decline from baseline: a 25% increase above the baseline (min. increase of 2 ng/mL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) at 4 Months (Instead of Time to PSA Progression) | 4 months | Due to the difficulties to assess biological progression date when clinical progression has occurred first, and because of the non-assessment of the clinical progression after treatment discontinuation, Time to PSA progression was not evaluated. PFS was evaluated instead, whether biological or clinical progression. |
| Progression Free Survival (PFS) at 4 Months (Instead of Time to Onset of Cancer-related Symptoms) | 4 months | Due to the difficulties to assess biological progression date when clinical progression has occurred first, and because of the non-assessment of the clinical progression after treatment discontinuation, Time to onset of cancer-related symptoms was not evaluated. PFS was evaluated instead, whether biological or clinical progression. |
| PSA Response Rate | 4 months | To investigate the effect of vandetanib on the PSA response rate. PSA response rate defined by the number of participants with a PSA decrease relative to baseline of at least 50%. A minimum decrease of 2 ng/mL in absolute value and a confirmation on at least 2 consecutive occasions (at least 4 weeks apart) were requested. |
| Number of Patients With CECs, CTCs and Gene Signature Profile of CTCs | 4 months | To investigate the relationship between response to vandetanib, CTCs and CECs. To investigate gene signature profile of antiangiogenic response by gene micro-array analysis of CTCs. Gene signature profile of CTCs was aimed to be compared before and after 2 months of treatment. No blood sample has been taken for the study, and so results on CTCs, CECs of tumour vessels and gene and signature profiles of CTCs were not performed. |
| Progression Rate From the Radionuclide Bone Scanning | 4 months | To describe the effect of vandetanib on progression rate from the radionuclide bone scanning in a sub-group of patients who had a bone scan within 3 to 6 months after 1st treatment dose. Number of participants with at least 2 new lesions on the radionuclide bone scan compared to baseline assessment were counted for calculation of progression rate. |
| Number of Circulating Tumour Cells (CTC) (in Patients Included in Ile de France Centres Only) | 4 months | To investigate the effect of vandetanib on CTC. Numbering of CTCs to be performed at baseline, 1 week, 1 and 2 months after randomisation. This study was proposed only to patients followed in a study centre located in Ile de France. Correlation between the number of CTCs and PSA response was to be estimated after 1 week, 1 and 2 months of treatment |
| Number of Circulating Endothelial Cells (CEC) of Tumour Blood Cells (in Patients Included in Ile de France Centres Only) | 4 months | To investigate the effect of vandetanib on CEC. Numbering of CECs was to be performed at baseline, 1 week, 1 month and 2 months after randomisation. Correlation between the number of CECs and PSA response was to be estimated after 1 week, 1 month and 2 months of treatment. |
| Overall Survival (OS) | End of study (July 2011) | To investigate the effect of vandetanib on overall survival. Patients alive at the time of the statistical analysis were censored at the time they were last known to be alive. Due to censored data, median overall survival in the placebo group cannot be calculated. OS defined as the number of participants who were alive. |
Countries
France
Participant flow
Recruitment details
From February 4th, 2008 to April 26th, 2010, 8 centers in France.
Pre-assignment details
110 participants screened; 95 participants were randomized to receive either bicalutamide 150 mg + vandetanib 300 mg once daily oral dose or bicalutamide 150 mg + placebo.
Participants by arm
| Arm | Count |
|---|---|
| Vandetanib Bicalutamide 150mg + Vandetanib (ZD6474) 300mg | 47 |
| Placebo Bicalutamide 150mg + placebo | 48 |
| Total | 95 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 11 | 6 |
| Overall Study | Lost to Follow-up | 1 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 2 |
Baseline characteristics
| Characteristic | Vandetanib | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 70.77 years STANDARD_DEVIATION 7.68 | 72.23 years STANDARD_DEVIATION 6.92 | 71.51 years STANDARD_DEVIATION 7.3 |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 47 Participants | 48 Participants | 95 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 47 / 48 | 47 / 47 |
| serious Total, serious adverse events | 17 / 48 | 4 / 47 |
Outcome results
Primary
Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months
To assess the effect of vandetanib on biological progression free rate based on PSA level (assessable set). PSA progression free rate defined as the number of participants with : * After decline from baseline: a 25% increase above the nadir * No decline from baseline: a 25% increase above the baseline (min. increase of 2 ng/mL)
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vandetanib | Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months | 8 Participants |
| Placebo | Prostate Specific Antigen (PSA) Progression Free Rate at 4 Months | 7 Participants |
Secondary
Number of Circulating Endothelial Cells (CEC) of Tumour Blood Cells (in Patients Included in Ile de France Centres Only)
To investigate the effect of vandetanib on CEC. Numbering of CECs was to be performed at baseline, 1 week, 1 month and 2 months after randomisation. Correlation between the number of CECs and PSA response was to be estimated after 1 week, 1 month and 2 months of treatment.
Time frame: 4 months
Population: This part of the study was proposed only to patients followed in one study centre located in Ile de France and finally no blood sample has been taken at this centre. So no data on CTCs, CECs were collected and no analysis was performed.
Secondary
Number of Circulating Tumour Cells (CTC) (in Patients Included in Ile de France Centres Only)
To investigate the effect of vandetanib on CTC. Numbering of CTCs to be performed at baseline, 1 week, 1 and 2 months after randomisation. This study was proposed only to patients followed in a study centre located in Ile de France. Correlation between the number of CTCs and PSA response was to be estimated after 1 week, 1 and 2 months of treatment
Time frame: 4 months
Population: This part of the study was proposed only to patients followed in one study centre located in Ile de France and finally no blood sample has been taken at this centre. So no data on CTCs, CECs were collected and no analysis was performed.
Secondary
Number of Patients With CECs, CTCs and Gene Signature Profile of CTCs
To investigate the relationship between response to vandetanib, CTCs and CECs. To investigate gene signature profile of antiangiogenic response by gene micro-array analysis of CTCs. Gene signature profile of CTCs was aimed to be compared before and after 2 months of treatment. No blood sample has been taken for the study, and so results on CTCs, CECs of tumour vessels and gene and signature profiles of CTCs were not performed.
Time frame: 4 months
Secondary
Overall Survival (OS)
To investigate the effect of vandetanib on overall survival. Patients alive at the time of the statistical analysis were censored at the time they were last known to be alive. Due to censored data, median overall survival in the placebo group cannot be calculated. OS defined as the number of participants who were alive.
Time frame: End of study (July 2011)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vandetanib | Overall Survival (OS) | 32 participants |
| Placebo | Overall Survival (OS) | 35 participants |
Secondary
Progression Free Survival (PFS) at 4 Months (Instead of Time to Onset of Cancer-related Symptoms)
Due to the difficulties to assess biological progression date when clinical progression has occurred first, and because of the non-assessment of the clinical progression after treatment discontinuation, Time to onset of cancer-related symptoms was not evaluated. PFS was evaluated instead, whether biological or clinical progression.
Time frame: 4 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Vandetanib | Progression Free Survival (PFS) at 4 Months (Instead of Time to Onset of Cancer-related Symptoms) | 12.2 weeks |
| Placebo | Progression Free Survival (PFS) at 4 Months (Instead of Time to Onset of Cancer-related Symptoms) | 12.8 weeks |
Secondary
Progression Free Survival (PFS) at 4 Months (Instead of Time to PSA Progression)
Due to the difficulties to assess biological progression date when clinical progression has occurred first, and because of the non-assessment of the clinical progression after treatment discontinuation, Time to PSA progression was not evaluated. PFS was evaluated instead, whether biological or clinical progression.
Time frame: 4 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Vandetanib | Progression Free Survival (PFS) at 4 Months (Instead of Time to PSA Progression) | 12.2 weeks |
| Placebo | Progression Free Survival (PFS) at 4 Months (Instead of Time to PSA Progression) | 12.8 weeks |
Secondary
Progression Rate From the Radionuclide Bone Scanning
To describe the effect of vandetanib on progression rate from the radionuclide bone scanning in a sub-group of patients who had a bone scan within 3 to 6 months after 1st treatment dose. Number of participants with at least 2 new lesions on the radionuclide bone scan compared to baseline assessment were counted for calculation of progression rate.
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vandetanib | Progression Rate From the Radionuclide Bone Scanning | 3 Participants |
| Placebo | Progression Rate From the Radionuclide Bone Scanning | 4 Participants |
Secondary
PSA Response Rate
To investigate the effect of vandetanib on the PSA response rate. PSA response rate defined by the number of participants with a PSA decrease relative to baseline of at least 50%. A minimum decrease of 2 ng/mL in absolute value and a confirmation on at least 2 consecutive occasions (at least 4 weeks apart) were requested.
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Vandetanib | PSA Response Rate | 3 Participants |
| Placebo | PSA Response Rate | 5 Participants |